(From left to right) Cellino co-founders Marinna Madrid, Nabiha Saklayen, and Matthias Wagner

February 1, 2021 08:00 AM EST

Khosla Ventures helps seed a next-gen regenerative medicines startup boasting AI-based stem cell culturing technology

Conner Mitchell

A startup in the bustling Boston-area biotech hub hopes its new technology has solved a time-consuming aspect of developing drugs that rely on cell therapy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Khosla Ventures helps seed a next-gen regenerative medicines startup boasting AI-based stem cell culturing technology

Conner Mitchell

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Khosla Ven­tures helps seed a next-gen re­gen­er­a­tive med­i­cines start­up boast­ing AI-based stem cell cul­tur­ing tech­nol­o­gy

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Khosla Ventures helps seed a next-gen regenerative medicines startup boasting AI-based stem cell culturing technology